MDM4 amplification in atypical lipomatous tumors/well‐differentiated liposarcoma: Private event or alternative oncogenic mechanism?
Authors:
Open Access
- 21 February 2023
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 62 (6) , 367-372
Abstract
Adipocytic tumors are the most common mesenchymal tumors in soft tissues. Among them, a diagnostic challenge relies in the distinction between lipoma and atypical lipomatous tumor (ALT)/well differentiated liposarcoma (WDLPS), as both entities are often undistinguishable not only from a radiological point of view, but also at the microscopic level and particularly when dealing with small tumor specimen. Thus, detection of recurrent MDM2 amplifications may be the only criteria to discriminate malignant tumors from lipomas. In this study, we report the case of a patient diagnosed with a well differentiated, adipocytic tumor located in the inferior limb and lacking MDM2 amplification, whose diagnosis was reclassified for ALT/WDLPS after identification of an alternative MDM4 amplification by comparative genomic hybridization profiling, whole exome sequencing and fluorescence in situ hybridization (FISH). Screening of a cohort of 37 large, deep‐seated, well‐differentiated adipocytic tumors previously classified as lipomas using RT‐qPCR and FISH failed to detect other cases of MDM4‐amplified ALT/WDLPS. This report shows that MDM4 amplification is an exceptional molecular event alternative to MDM2 amplification in ALT/WDLPS. This alteration should be considered and looked for in suspicious adipocytic tumors to optimize their surgical management.Keywords
Funding Information
- Groupement des Entreprises Françaises dans la lutte contre le Cancer
- Institut National de la Santé et de la Recherche Médicale
This publication has 14 references indexed in Scilit:
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue SarcomasCell, 2017
- MDM4 amplification in a case of de‐differentiated liposarcoma and in‐silico data supporting an oncogenic event alternative to MDM2 amplification in a subset of casesHistopathology, 2017
- Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistryHuman Pathology, 2017
- Differentiation of Lipoma From Liposarcoma on MRI Using Texture and Shape AnalysisAcademic Radiology, 2014
- MDM2, MDMX and p53 in oncogenesis and cancer therapyNature Reviews Cancer, 2013
- Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?Laboratory Investigation, 2010
- Detection of MDM2-CDK4 Amplification by Fluorescence In Situ Hybridization in 200 Paraffin-embedded Tumor Samples: Utility in Diagnosing Adipocytic Lesions and Comparison With Immunohistochemistry and Real-time PCRAmerican Journal of Surgical Pathology, 2007
- MDM2 and CDK4 Immunostainings Are Useful Adjuncts in Diagnosing Well-Differentiated and Dedifferentiated Liposarcoma SubtypesAmerican Journal of Surgical Pathology, 2005
- The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipomaBritish Journal of Cancer, 2000
- Complex composition and co‐amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well‐differentiated liposarcomaGenes, Chromosomes and Cancer, 1994